A Phase 4 interventional study of Paclitaxel in Breast Neoplasm Female, sponsored by University of Wisconsin, Madison. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.
Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 206th largest by planned enrollment of the 361 interventional ones that give a count, is one of 10 that started in 2017, is one of 10 in phase 4, reaches primary completion later than 38 of the 59 other live ones, and was the 285th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18+
Liu Shu · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 249 · Phase 3 69 · Phase 4 10
First in 1994; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 361 interventional studies. Of the 254 that completed or were terminated, 125 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 373 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
52 studies in Breast Neoplasms by University of Wisconsin, Madison: 6 open now, 7 under way, none of them phase 3. Of 43 finished, 13 (30%) have results posted.
Among the 52 studies in Breast Neoplasms by University of Wisconsin, Madison, this one is the 15th largest by planned enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2017, is one of 2 in phase 4, and was the 29th registered.
University of Wisconsin, Madison’s Breast Neoplasms studies by the year they started, since 1998.
16 of the studies testing paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT03125928Fox Chase Cancer CenterClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | 2026-12 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT07580833Health Hope PharmaA Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors | 2026-12 |
| NCT05383196Antonio Giordano, MDOnvansertib + Paclitaxel In TNBC | 2026-12-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 373 studies testing paclitaxel in Breast Neoplasms, from their registry updates:
Among University of Wisconsin, Madison’s 52 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Primary Objectives
Secondary Objectives
Initial Actual Primary and Study Completion Date registered as 8/16/2022 with 24 participants enrolled.
Per a Protocol Amendment dated 5/7/24, this study will re-open to enroll up to 50 participants. NCI funding and data sharing information added.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle. Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery.
Drug: Paclitaxel
Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
Also known as: Taxol
Response to Paclitaxel
To test if high cancers with high chromosomal instability (CIN) respond to paclitaxel better than low CIN cancers. Response determined by the percent decrease in linear measurement of tumor size on the greatest dimension per RECIST-like criteria
Time frame: Up to 3 months
Tumor Level Difference of Paclitaxel
Identify patient-specific differences in tumor levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.
Time frame: Up to 1 day
Non-Tumor Level Difference of Paclitaxel
Identify patient-specific differences in non-tumor (plasma) levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.
Time frame: Up to 1 day
Paclitaxel Levels
Paclitaxel levels at the first dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing difference at two time points within the same patient with paired statistics.
Time frame: Up to 79 days
Antimitotic Effects
Compare pre-existing versus post-treatment antimitotic effects at 20 hours after the 1st dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by tissue analysis of tumor samples with phospho-histone H3 and stains for spindle morphology to quantify mitotic index and mitotic characteristics at two time points using paired statistical analysis.
Time frame: Up to 79 days
Mitotic Index
The mitotic index is a measure of cells arresting in mitosis, previously thought to be the major mechanism of taxol action. It is defined as the percentage of cells undergoing mitosis in a given population of cells. An elevated mitotic index indicates more cells are at this phase of the cell cycle at the time of sampling.
Time frame: Baseline and 20 hours post-first dose
Correlate Drug Levels With Aneuploidy of Tumor
Correlate pathologic response and clinical response with biomarkers including aneuploidy
Time frame: Up to 3 months
Correlate Drug Levels With Chromosomal Instability of Tumor
Correlate pathologic response and clinical response with biomarkers including CIN
Time frame: Up to 3 months
Ki67 of Tumor
The Ki-67 protein is a cellular marker for proliferation. Ki-67 is an excellent marker to determine the growth fraction of a given cell population. The fraction of Ki-67-positive tumor cells (the Ki-67 labeling index) is often correlated with the clinical course of cancer.
Time frame: Up to 3 months
Change in CIN Levels
There are many proposed ways to measure CIN. Here, we used # of multipolar spindles as a surrogate of CIN measures.
Time frame: Baseline and 20 hours post-first dose
| Milestone | Weekly Paclitaxel |
|---|---|
| Started | 24 |
| Paclitaxel concentration determine | 15 |
| Analyzed after first dose | 16 |
| Analyzed after third dose | 5 |
| Analyzed after twelfth dose | 1 |
| Completed | 24 |
| Not completed | 0 |
To test if high cancers with high chromosomal instability (CIN) respond to paclitaxel better than low CIN cancers. Response determined by the percent decrease in linear measurement of tumor size on the greatest dimension per RECIST-like criteria
| percent decrease in tumor size | Weekly Paclitaxel |
|---|---|
| Response to Paclitaxel | -29.63 (-70.21 to 30) |
Identify patient-specific differences in tumor levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.
| micromolar | Weekly Paclitaxel |
|---|---|
| Participant 1 | 1.07 |
| Participant 2 | 0.34 |
| Participant 3 | 0.80 |
| Participant 4 | 0.57 |
| Participant 6 | 3.43 |
| Participant 7 | 1.55 |
| Participant 8 | 0.53 |
| Participant 9 | 0.63 |
| Participant 11 | 0.57 |
| Participant 13 | 1.67 |
| Participant 14 | 0.52 |
| Participant 15 | 1.20 |
| Participant 5 | NA |
| Participant 12 | NA |
Identify patient-specific differences in non-tumor (plasma) levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.
| micromolar | Weekly Paclitaxel |
|---|---|
| Participant 1 | 0.023 |
| Participant 2 | 0.040 |
| Participant 3 | 0.030 |
| Participant 4 | 0.027 |
| Participant 5 | 0.031 |
| Participant 6 | 0.020 |
| Participant 7 | 0.013 |
| Participant 8 | 0.011 |
| Participant 9 | 0.020 |
| Participant 11 | 0.038 |
| Participant 12 | 0.040 |
| Participant 13 | 0.094 |
| Participant 14 | 0.048 |
| Participant 15 | 0.035 |
Paclitaxel levels at the first dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing difference at two time points within the same patient with paired statistics.
| micromolars | Weekly Paclitaxel |
|---|---|
| First dose plasma paclitaxel | 0.041 (0.014 to 0.094) |
| Third dose plasma paclitaxel | 0.029 (0.013 to 0.062) |
| First dose intratumoral paclitaxel | 0.785 (0.34 to 1.67) |
| Third dose intratumoral paclitaxel | 1.21 (0.12 to 2.40) |
Compare pre-existing versus post-treatment antimitotic effects at 20 hours after the 1st dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by tissue analysis of tumor samples with phospho-histone H3 and stains for spindle morphology to quantify mitotic index and mitotic characteristics at two time points using paired statistical analysis.
| number of mitotic cells | Weekly Paclitaxel - Baseline | Weekly Paclitaxel - 20 Hours After First Dose | Weekly Paclitaxel - 20 Hours After Third Dose | Weekly Paclitaxel - 20 Hours After Twelfth Dose |
|---|---|---|---|---|
| Participant 1 | 113 | 109 | — | — |
| Participant 2 | 41 | 100 | 32 | — |
| Participant 3 | 100 | 104 | 105 | — |
| Participant 4 | 101 | 103 | — | — |
| Participant 6 | 106 | 108 | — | — |
| Participant 7 | 79 | 103 | — | — |
| Participant 8 | 75 | 27 | — | — |
| Participant 9 | 35 | 63 | — | — |
| Participant 11 | 6 | 11 | — | — |
| Participant 12 | 24 | 30 | — | — |
| Participant 13 | 106 | 110 | 101 | — |
| Participant 14 | 86 | 102 | 20 | — |
| Participant 15 | 116 | 101 | — | — |
| Participant 16 | 106 | 104 | — | — |
| Participant 18 | 42 | 214 | 23 | 8 |
| Participant 19 | 30 | 70 | — | — |
The mitotic index is a measure of cells arresting in mitosis, previously thought to be the major mechanism of taxol action. It is defined as the percentage of cells undergoing mitosis in a given population of cells. An elevated mitotic index indicates more cells are at this phase of the cell cycle at the time of sampling.
| mitotic index | Weekly Paclitaxel - Pre-treatment | Weekly Paclitaxel - 20 Hours Post-first Dose |
|---|---|---|
| Participant 1 | 1.4 | 2.6 |
| Participant 2 | 1 | 3.379722 |
| Participant 3 | 1.35 | 4.4 |
| Participant 4 | 1.8 | 3.192745 |
| Participant 6 | 1.052765 | 2.305837 |
| Participant 7 | 1.2 | 3.201638 |
| Participant 8 | 0.6 | 1.29731 |
| Participant 9 | 1.466667 | 1.872558 |
| Participant 11 | 0.198311 | 0.32 |
| Participant 12 | 0.32 | 1.44 |
| Participant 13 | 2 | 4.2 |
| Participant 14 | 1.48 | 2.87 |
| Participant 15 | 1.33 | 5.56 |
Correlate pathologic response and clinical response with biomarkers including aneuploidy
No measurements were reported for this outcome.
Correlate pathologic response and clinical response with biomarkers including CIN
No measurements were reported for this outcome.
The Ki-67 protein is a cellular marker for proliferation. Ki-67 is an excellent marker to determine the growth fraction of a given cell population. The fraction of Ki-67-positive tumor cells (the Ki-67 labeling index) is often correlated with the clinical course of cancer.
| Percentage of Ki67 + cells | Weekly Paclitaxel |
|---|---|
| Participant 1 | 90 |
| Participant 2 | 80 |
| Participant 3 | 90 |
| Participant 6 | 45 |
| Participant 7 | 90 |
| Participant 8 | 60 |
| Participant 9 | 15 |
| Participant 11 | 20 |
| Participant 12 | 25 |
| Participant 13 | 90 |
| Participant 14 | 60 |
| Participant 15 | 60 |
There are many proposed ways to measure CIN. Here, we used # of multipolar spindles as a surrogate of CIN measures.
| % of cells with multipolar spindles | Weekly Paclitaxel Pre-treatment | Weekly Paclitaxel - 20 Hours After First Dose |
|---|---|---|
| Participant 1 | 7.08 | 51.38 |
| Participant 2 | 2.44 | 49 |
| Participant 3 | 2.44 | 26.92 |
| Participant 4 | 3.96039604 | 29.12621359 |
| Participant 6 | 16.98113208 | 60.18518519 |
| Participant 7 | 3.797468354 | 64.0776699 |
| Participant 8 | 5.33333333 | 62.96296296 |
| Participant 9 | 8.571428571 | 61.9047619 |
| Participant 11 | 0 | 27.27 |
| Participant 12 | 4.2 | 56.6 |
| Participant 13 | 5.6 | 64.5 |
| Participant 14 | 13.95 | 58.82 |
| Participant 15 | 3.45 | 60.4 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Weekly Paclitaxel | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Age, Customized(Participants) | Weekly Paclitaxel |
|---|---|
| 20-29 years | 1 |
| 30-39 years | 4 |
| 40-49 years | 7 |
| 50-59 years | 7 |
| 60-69 years | 2 |
| 70-79 years | 3 |
| Sex: Female, Male(Participants) | Weekly Paclitaxel |
|---|---|
| Female | 24 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Weekly Paclitaxel |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Weekly Paclitaxel |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 22 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Weekly Paclitaxel |
|---|---|
| United States | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Started Mar 2017 (actual). Primary completion is estimated for Jun 2027, 123 months after the start.
Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 123 months is above that.
Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel
University of Wisconsin, Madison →